Loading clinical trials...
Loading clinical trials...
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Effect of Lepodisiran on the Reduction of Major Adverse Cardiovascular Events in Adults With Elevated Lipoprotein(a) Who Have Established Atherosclerotic Cardiovascular Disease or Are at Risk for a First Cardiovascular Event - ACCLAIM-Lp(a)
Conditions
Interventions
Lepodisiran Sodium
Placebo
Locations
933
United States
Birmingham Clinical Research
Birmingham, Alabama, United States
Alliance for Multispecialty Research, LLC
Daphne, Alabama, United States
SEC Clinical Research
Dothan, Alabama, United States
Alliance for Multispecialty Research, LLC
Mobile, Alabama, United States
Mobile Heart Specialists
Mobile, Alabama, United States
Prime Medical Group, LLC dba Gilbert Center for Family Medicine, LLC
Gilbert, Arizona, United States
Start Date
March 5, 2024
Primary Completion Date
March 1, 2029
Completion Date
March 1, 2029
Last Updated
April 20, 2026
NCT06813911
NCT06930885
NCT06482476
NCT07311330
NCT05834673
Lead Sponsor
Eli Lilly and Company
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions